Johnson & Johnson

Funding reported, $785M, last update 2 weeks ago

Pharma biotech · Headquarters United States

Everything we hold on Johnson & Johnson, newest first. Every line links to the filing or report it came from.

This profile is thin because we hold one source document on Johnson & Johnson so far, not because nothing else has happened there. We only publish what we have read on a primary source and can link to. So a profile fills up as filings and reports come in, and we never seed it from an estimate. We keep profiles at this stage out of our sitemap and mark them noindex until they carry enough to be worth a search result of their own.

1. 2026-07-30
   Headcount Not Stated Growing and expanding

   J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech

   Johnson & Johnson is paying $785 million upfront for an option to buy Flagship's in vivo CAR-T biotech Sail Biomedicines, expanding its cell therapy pipeline, but the announcement names no hiring plans.

   United States · $785M raised · News Report · Endpoints News · No archive snapshot yet. We re-check weekly; next check by Aug 23.

The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker